Project: nciOncology
Class Immunosuppressant

Concrete Class Extends 

        Biological_Response_Modifier

 

Direct Instances:

None

 

Direct Subclasses:

1. Peldesine
2. Cycloleucine
3. Anaxirone
4. Sirolimus
5. Corticosteroid_Therapeutic_
6. Mycophenolic_Acid
7. Mycophenolate_Mofetil
8. Thioinosine
9. Didemnin_B
10. Gusperimus
11. Etanercept
12. Thalidomide
13. Daclizumab
14. Interleukin-1_Receptor_Antagonist
15. Cyclophosphamide
16. CCI-779
17. Antithymocyte_Globulin
18. L-Leucyl-L-Leucine_Methyl_Ester
19. CC-5013
20. Flavopiridol
21. Tacrolimus
22. Mercaptopurine
23. Azathioprine
24. Beauvericin
25. Cyclosporine
26. Vesnarinone

Template Slots
Slot name	Documentation	Type	Allowed Values/Classes	Cardinality	Default
rChemical_or_Drug_Has_Biochemical_Class_or_Structure		Instance	Chemicals_and_Drugs_Kind	0:*
rChemical_or_Drug_Has_Target_Protein		Instance	Protein_Kind	0:*
rChemical_or_Drug_Has_Target_Anatomy		Instance	Anatomy_Kind	0:*
rChemical_or_Drug_Affects_Cell_Type_or_Tissue		Instance	Anatomy_Kind	0:*
rChemical_or_Drug_Has_Source		Instance	Organism_Kind	0:*
rChemical_or_Drug_Has_Target_Organism		Instance	Organism_Kind	0:*
rChemical_or_Drug_Plays_Role_in_Biological_Process		Instance	Biological_Process_Kind	0:*
rChemical_or_Drug_Has_Biochemical_Function		Instance	Protein_Kind	0:*
rChemical_or_Drug_Has_Receptor		Instance	Protein_Kind	0:*
rChemical_or_Drug_Has_Associated_Pathology		Instance	Findings_and_Disorders_Kind	0:*
rChemical_or_Drug_FDA_Approved_for_Disease		Instance	Findings_and_Disorders_Kind	0:*
rChemical_or_Drug_is_Part_of_Chemical_or_Drug		Instance	Chemicals_and_Drugs_Kind	0:*

Own Slots
Slot name	Documentation	Type	Value	Cardinality
:OWL-DISJOINT-CLASSES		Instance

Return to class hierarchy